

## PATENT ASSIGNMENT

Electronic Version v1.1  
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
Unigene Laboratories, Inc.	06/11/2013
RECEIVING PARTY DATA	
Name:	UGP Therapeutics, Inc.
Street Address:	227 W. Monroe Street, Suite 3900
City:	Chicago
State/Country:	ILLINOIS
Postal Code:	60606
PROPERTY NUMBERS Total: 14	
Property Type	Number
Patent Number:	5912014
Patent Number:	8088734
Patent Number:	RE40812
Patent Number:	RE43580
Patent Number:	7553655
Patent Number:	8252580
Patent Number:	8076291
Patent Number:	8217139
Patent Number:	8378067
Application Number:	13219132
Application Number:	13544256
Application Number:	13238801
Application Number:	13524381
PCT Number:	US2012042699
CORRESPONDENCE DATA	

502429757

PATENT  
 REEL: 030856 FRAME: 0340

CH \$560.00 5912014

Fax Number: 3129021061

*Correspondence will be sent via US Mail when the fax attempt is unsuccessful.*

Phone: 312-902-5665

Email: becky.williams@kattenlaw.com

Correspondent Name: Becky A. Williams

Address Line 1: 525 W. Monroe Street, Suite 1900

Address Line 4: Chicago, ILLINOIS 60661

NAME OF SUBMITTER:

Becky A. Williams

Signature:

/baw/

Date:

07/23/2013

Total Attachments: 6

source=UGP - Patent Assignment#page1.tif

source=UGP - Patent Assignment#page2.tif

source=UGP - Patent Assignment#page3.tif

source=UGP - Patent Assignment#page4.tif

source=UGP - Patent Assignment#page5.tif

source=UGP - Patent Assignment#page6.tif

## PATENT ASSIGNMENT

THIS PATENT ASSIGNMENT is made this 11th day of June, 2013, by and between Unigene Laboratories, Inc., a Delaware corporation ("**Assignor**"), in favor of UGP Therapeutics, Inc. ("**Assignee**").

WHEREAS, Assignor wishes to sell, transfer and assign, and Assignee wishes to assume and purchase all of Assignor's right, title and interest in and to the patents and patent applications listed on Schedule A attached hereto (collectively, "**Patents**").

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Assignor has sold, assigned, transferred and set over, and does hereby sell, assign, transfer and set over, unto the said Assignee all of Assignor's right, title and interest in, to and under the inventions set forth in the Patents, the Patents and all divisionals, continuations, re-examinations, renewals, provisionals, continuations in part and reissues thereof, and all Letters Patent of the United States and countries foreign to the United States which may be granted thereon and all divisionals, continuations, re-examinations, renewals, provisionals, continuations in part and reissues thereof (and including, without limitation, all proceeds thereof and the rights to sue for past, present and future infringements), and all applications for Letters Patent which may hereafter be filed for said inventions and Patents in any country or countries foreign to the United States, and all Letters Patent which may be granted for said inventions and Patents in any country or countries foreign to the United States, and requests the Commissioner of Patents of the United States, and any Official of any country or countries foreign to the United States, whose duty it is to issue patents on applications as aforesaid, to record the Assignee as the owner of all such Patents and issue all Letters Patent for said Patents to the said Assignee, as assignee of the Patents, for the sole use of the Assignee, its successors, legal representatives and assigns, in accordance with the terms of this instrument.


Assignor further agrees without further consideration to execute such further assignments and other lawful documents as the Assignee may from time to time reasonably request to effect fully this Assignment and to permit the Assignee to be duly recorded as the registered owner of the Patents in the countries in which such Patents are currently registered and all other rights hereby conveyed.

*[Signature Page Follows]*

IN WITNESS WHEREOF, the undersigned has caused this Assignment to be executed and delivered as of the date first written above.

UNIGENE LABORATORIES, INC.  
By: Victory Park Management, its attorney-in-fact

By: Matthew Ray  
Name: Matthew Ray  
Title: Manager



Ariene E. Pappalardo  
Notary Public  
My Commission Expires 1/4/2016

## SCHEDULE A

### Issued U.S. Patents

<u>Patent Name</u>	<u>Country</u>	<u>Issue Date</u>	<u>Patent Number</u>
Oral Salmon Calcitonin Pharmaceutical Products (AKA: ORAL SALM CAL)	United States	6/15/99	5,912,014
Oral Delivery of Peptides (AKA: ORAL AMIDATED)	United States	1/3/12	8,088,734
Nasal Calcitonin Formulation (AKA: NAS CAL)	United States	6/30/09	RE40812
Nasal Calcitonin Formulations (AKA: NAS CAL)	United States	8/14/12	RE43,580
Bacterial Host Cell for the Direct Expression of Peptides (AKA: HOST)	United States	6/30/09	7,553,655
Bacterial Host Cell for the Direct Expression of Peptides (AKA: HOST)	United States	8/28/12	8,252,580
Treatment for Obesity (AKA: AMYTONIN)	United States	12/13/11	8,076,291
Treatment for Obesity (AKA: AMYTONIN)	United States	7/10/12	8,217,139
Treatment for Obesity (AKA: AMYTONIN)	United States	2/19/13	8,378,067

**U.S. Patent Applications**

<b><u>Name</u></b>	<b><u>Country</u></b>	<b><u>Filing Date</u></b>	<b><u>Application Number</u></b>
Oral Delivery of Peptide Pharmaceutical Compositions (AKA: ORAL DALDA)	United States	8/26/11	13/219,132
Methods of Treating Medical Conditions Using Peptides (AKA: AMYTONIN)	United States	7/9/12	13/544,256
Calcitonin Products and Therapies for Treating Inflammatory or Degenerative Diseases (AKA: INFLAM)	United States	9/21/11	13/238,801
Anti-Inflammatory Pharmaceutical Products (AKA: ANNEXIN)	United States	6/15/12	13/524,381

**Foreign Issued Patents**

<b><u>Patent Name</u></b>	<b><u>Jurisdiction</u></b>	<b><u>Issue Date</u></b>	<b><u>Patent Number</u></b>
ORAL AMIDATED	Canada	11/30/12	2,512,824
NAS CAL	Canada	1/3/12	2,399,505
NAS CAL	China	1/12/05	ZL01807605.X

**Foreign Patent Applications**

<b><u>Name</u></b>	<b><u>Jurisdiction</u></b>	<b><u>Application Number</u></b>
AMYTONIN	Australia	2010206614
AMYTONIN	Brazil	N/A
AMYTONIN	Canada	2,750,035
AMYTONIN	China	201080005151.6
AMYTONIN	Europe	10733943.4
AMYTONIN	India	3198/KOLNP/2011
AMYTONIN	Japan	2011-548156
AMYTONIN	Korea	2011-7018879
ANNEXIN	PCT	PCT/US2012/42699